Category: Top Story
-

Freeport-McMoRan to benefit from stronger copper and gold prices
HSBC upgraded Freeport-McMoRan (NYSE:FCX) to Buy from Hold and raised its price target to $50 from $43, citing a supportive environment for copper and gold prices that should bolster earnings, even as the miner faces operational setbacks at its flagship Grasberg mine in Indonesia. Copper has outperformed other base and bulk metals this year amid…
-

Taoping Inc. stock falls after announcing non-binding acquisition LOI
Taoping Inc. (NASDAQ:TAOP) shares dropped 8.4% in premarket trading on Friday after the company revealed it had signed a non-binding Letter of Intent (LOI) to acquire Alphalion Holding Limited. Under the proposed transaction, Taoping would acquire 100% of Alphalion’s equity. The deal remains contingent on due diligence, negotiation of a definitive agreement, and standard closing…
-

Protalix BioTherapeutics Inc stock plunges after CHMP rejects alternative Elfabrio dosing regimen
Protalix BioTherapeutics Inc (AMEX:PLX) shares tumbled 20.8% in premarket trading on Friday after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the company’s application to approve an alternative dosing schedule for its Fabry disease therapy Elfabrio. The CHMP rejected Protalix’s proposal for a…
-

Avita Medical Ltd stock tumbles after CEO exit and Board shake-up
Avita Medical Ltd (NASDAQ:RCEL) shares plunged 21.9% in premarket trading on Friday after the company announced a sudden leadership transition and major Board changes. The wound care therapeutics firm said Chairman Cary Vance has been appointed Interim Chief Executive Officer, replacing Jim Corbett, who is stepping down from both his CEO role and his seat…
-

XORTX Therapeutics Inc stock soars after acquiring renal anti-fibrotic program
XORTX Therapeutics Inc (NASDAQ:XRTX) shares surged 40% in premarket trading on Friday after the company announced it had signed a binding term sheet to acquire a Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems Limited. As part of the deal, the late-stage clinical pharmaceutical firm will gain rights to VB4-P5 — a novel new chemical entity…
-

Sealsq Corp stock soars after unveiling IC’Alps integration strategy
Sealsq Corp (NASDAQ:LAES) shares climbed 10.2% in premarket trading on Friday after the company revealed its integrated strategy for IC’Alps, the French ASIC design house it recently acquired. The plan positions Sealsq as the only firm able to provide secure hardware solutions across Catalog ICs, Custom ICs, and Security IP. The semiconductor and post-quantum cryptography…
-

Safe & Green Holdings Corp. stock surges after completing AI-powered wellsite system
Safe & Green Holdings Corp. (NASDAQ:SGBX) shares jumped 25.9% in premarket trading on Friday after the company announced it had completed Phase 1 of its intelligent wellsite monitoring system. The AI-driven platform was developed through its wholly owned subsidiary, Olenox Corp.. It uses a proprietary algorithm to analyze water-cut percentages and automatically adjust pumpjack operations…
-

AST SpaceMobile stock dips after Barclays issues double downgrade
AST SpaceMobile (NASDAQ:ASTS) shares fell about 3% in early trading on Friday after Barclays downgraded the satellite communications company two notches — from Overweight to Underweight — and set a price target of $60. That target implies a sharp downside from its previous closing price of $89.50. The downgrade from analyst Mathieu Robilliard comes despite…
-

Fifth Third Bancorp earnings rise as investor concerns linger over regional banks
Fifth Third Bancorp (NASDAQ:FITB) reported stronger-than-expected third-quarter results on Friday, supported by lower deposit costs that helped boost net interest income. However, the bank also flagged a loss tied to a loan extended to bankrupt auto dealer Tricolor, which weighed on sentiment around regional lenders. The Ohio-based bank — along with many of its peers…
-

State Street Corporation beats Q3 forecasts as revenue climbs 9%
State Street Corporation (NYSE:STT) reported stronger-than-expected third-quarter 2025 results on Thursday, driven by broad-based growth in fee income across its core business lines. Despite the solid numbers, the stock slipped about 2.7% after the announcement. The Boston-based custody bank and asset manager posted adjusted earnings per share of $2.78, topping analyst expectations of $2.63 by…